Fda Approved - Search News

type 2 diabetes, chronic kidney disease and FDA

US FDA approves Novo Nordisk's Ozempic to cut risk of diabetic kidney disease progression

The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as death due to heart problems in diabetes patients with chronic kidney disease (CKD),

CNN on MSN · 9h

FDA approves Ozempic to reduce risks from chronic kidney disease in diabetes patients

Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the US Food and Drug Administration to reduce certain risks associated with chronic kidney disease,

U.S. News & World Report · 10h

US FDA Approves Novo Nordisk's Diabetes Drug to Reduce Risk of Worsening Kidney Disease

(Reuters) - Novo Nordisk said on Tuesday the U.S. FDA has approved its diabetes drug Ozempic to reduce the risk of worsening kidney disease and death due to cardiovascular disease in adults with type 2 diabetes and chronic kidney disease.

FDA approves antidepressant nasal spray

Medical News Today · 1d

FDA-approved nasal spray for severe depression can lead to remission

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in people who have not responded to at least two oral antidepressants.

Popular Science · 6d

FDA approves first-of-its-kind nasal spray for severe depression

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD, and similar psychiatric conditions.

Yahoo · 16h

FDA approves antidepressant nasal spray | Morning in America

The FDA has approved the use of Spravato, an antidepressant nasal spray, as a standalone treatment for depression in the U.S. Sue Varma discusses why she supports the use of the drug and how it may help those suffering from depression.

FDA, breast cancer

Healio · 14h

FDA expands Enhertu approval for breast cancer

The FDA expanded the approval of trastuzumab deruxtecan for treatment of breast cancer.The new indication applies to use of the agent by patients with HER2-low or HER2-utralow metastatic breast cancer whose disease progressed after at least one endocrine therapy.

The American Journal of Manag… · 15h

FDA Approves Trastuzumab Deruxtecan for HER2-Low/Ultralow Breast Cancer

The approval is based on findings from a phase 3 study which demonstrated the drug’s superiority over chemotherapy.

Business Insider · 1d

FDA Approves AstraZeneca And Daiichi Sankyo's ENHERTU For HER2-Low/Ultralow Breast Cancer

The U.S. Food and Drug Administration has approved AstraZeneca Plc. (AZN.L, AZN) and Daiichi Sankyo's (DSKYF.PK) ENHERTU

SheFinds on MSN5d

3 ‘Toxic, FDA-Approved’ Breakfast Foods That Are ‘Banned In Other Countries’ No One Should Be Buying In 2025: Frosted Flakes, More

Breakfast might be the most important meal of the day, but what you eat is just as crucial. While there are plenty of healthy ...

STAT1d

U.S. health agencies see some chaos — but an FDA approval gets through

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Texas Public Radio1d

The FDA pulls key DEI initiative for cancer studies from its website

A Food and Drug Administration project to promote diversity in clinical studies of cancer treatments was removed from the ...

Cure Today4d

FDA Approves GRAFAPEX/Fludarabine Before alloHSCT in AML and MDS

The FDA has approved GRAFAPEX™ and fludarabine as a preparative regimen in acute myeloid leukemia or myelodysplastic syndrome ...

Charlotte’s Web Founder Aims For FDA Approval Of Autism Spectrum Disorder Drug

Joel Stanley, the founder and former CEO of Charlotte’s Web, is leading an effort to achieve approval from the FDA for a novel treatment to treat autism spectrum ...

manilatimes2d

FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease

LEQEMBI ® [ (lecanemab-irmb) 100 mg/mL injection for intravenous use] is indicated for the treatment of Alzheimer's disease (AD). Treatment with LEQEMBI should be initiated in patients with mild ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

type 2 diabetes, chronic kidney disease and FDA

FDA approves antidepressant nasal spray

FDA, breast cancer

Related topics